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Abstract
Background: In the absence of stand-alone infrastructures for delivering cervical cancer screening services, efforts are
underway in sub-Saharan Africa to dovetail screening with ongoing vertical health initiatives like HIV/AIDS care programs.
Yet, evidence demonstrating the utilization of cervical cancer prevention services in such integrated programs by women of
the general population is lacking.
Methods: We analyzed program operations data from the Cervical Cancer Prevention Program in Zambia (CCPPZ), the
largest public sector programs of its kind in sub-Saharan Africa. We evaluated patterns of utilization of screening services by
HIV serostatus, examined contemporaneous trends in screening outcomes, and used multivariable modeling to identify
factors associated with screening test positivity.
Results: Between January 2006 and April 2011, CCPPZ services were utilized by 56,247 women who underwent cervical
cancer screening with visual inspection with acetic acid (VIA), aided by digital cervicography. The proportion of women
accessing these services who were HIV-seropositive declined from 54% to 23% between 2006–2010, which coincided with
increasing proportions of HIV-seronegative women (from 22% to 38%) and women whose HIV serostatus was unknown
(from 24% to 39%) (all p-for trend,0.001). The rates of VIA screening positivity declined from 47% to 17% during the same
period (p-for trend ,0.001), and this decline was consistent across all HIV serostatus categories. After adjusting for
demographic and sexual/reproductive factors, HIV-seropositive women were more than twice as likely (Odds ratio 2.62, 95%
CI 2.49, 2.76) to screen VIA-positive than HIV-seronegative women.
Conclusions: This is the first ‘real world’ demonstration in a public sector implementation program in a sub-Saharan African
setting that with successful program scale-up efforts, nurse-led cervical cancer screening programs targeting women with
HIV can expand and serve all women, regardless of HIV serostatus. Screening program performance can improve with
adequate emphasis on training, quality control, and telemedicine-support for nurse-providers in clinical decision making.
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Introduction
Invasive cervical cancer (ICC) is a leading cause of cancer-
related mortality and morbidity among women in the developing
world [1,2]. Simplified ‘‘screen and treat’’ approaches [such as
visual inspection with acetic acid (VIA) and immediate cryother-
apy] for secondary prevention of cervical cancer have been
developed for field adoption in resource-constrained settings where
implementation and expansion of cytology (Pap smear)-based
screening programs have proven unsustainable and human
papillomavirus (HPV) testing is not yet available [3–8].
Stand-alone infrastructures for delivering public sector-based
cervical cancer screening services are largely unavailable or poorly
developed in most low and middle income countries [2]. In
response, several international efforts are currently underway in
sub-Saharan Africa to dovetail cervical cancer screening with
ongoing vertical health initiatives, prominently with HIV/AIDS
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care and treatment programs [8–10]. In general, HIV-seropositive
women are at increased risk of HPV persistence and cervical
cancer incidence. Access to affordable combination antiretroviral
therapy (cART) over the past decade has led to longer lifespans
among HIV-seropositive women. Yet, they continue to be at
higher risk for cervical cancer given lack of access to cervical
cancer screening [11,12]. Thus, provision of cervical cancer
screening is a clinical care imperative for HIV-seropositive
women. Several efforts have been undertaken in the past decade
to develop cervical cancer screening infrastructures linked to
HIV/AIDS care and treatment programs and targeting HIV-
seropositive women, but open for access to all women, regardless
of HIV serostatus [8–10,13–17]. Nonetheless, evidence demon-
strating the utilization and uptake of cervical cancer services
offered in this format by women of the general population, beyond
those who are HIV-seropositive, is lacking.
Zambia, a sub-Saharan African nation with a population over
13 million, has the world’s second highest annual cervical cancer
incidence and mortality rates [1], as well as a generalized HIV/
AIDS epidemic [18]. In 2006, the Cervical Cancer Prevention
Program in Zambia (CCPPZ) was initiated as an innovative public
sector service platform, built within and tightly integrated to U.S.
President’s Emergency Plan for AIDS Relief (PEPFAR)-supported
HIV/AIDS care and treatment infrastructures [10]. Notwith-
standing the physical co-location of the CCPPZ clinics with HIV/
AIDS clinics, cervical cancer screening services are open to all
women, regardless of their HIV serostatus. In CCPPZ clinics,
trained nurses provide ‘screen-and-treat’ services on the same day,
or refer cryotherapy-ineligible women for further diagnostic
evaluation and treatment to an outpatient surgery clinic located
in a tertiary hospital. Over the course of seven years (2006 to
present: June 2013), CCPPZ has provided screening services to
over 100,000 women, and is the largest of such programs in sub-
Saharan Africa.
We sought to evaluate the utilization of screening services by
Zambian women stratified by HIV serostatus and examine the
trends and factors associated with screening-test positivity over the
program scale-up period, with a goal to inform the roll-out of
similar programs being implemented in other resource constrained
settings.
Methods
The operational details of CCPPZ have been reported in
previous manuscripts [10,19–21]. Briefly, trained female Zambian
nurses perform screening of women with VIA aided by digital
camera enhancement of the cervix (digital cervicography). A same-
day treatment by cryotherapy is offered to eligible VIA-positive
women, and those ineligible for cryotherapy are referred to an
outpatient Gynecologic Cancer Prevention Clinic for histopatho-
logical evaluation by biopsy or loop electrosurgical excision
procedure (LEEP). Participant clinical and demographic informa-
tion is entered electronically, at the point of care, into a database
by community health workers and nurses that is updated weekly.
Women attending CCPPZ clinics are asked to self-report HIV-
status, and HIV- negative or indeterminate status women who
agree to be tested are provided an on-site HIV test by the CCPPZ
nurses. Thus, although HIV serostatus confirmation is by self-
report, most HIV-seropositive women are ‘linked’ to the HIV/
AIDS care and treatment clinics co-located and operational in the
same premises.
For this study, for evaluating programmatic outcomes we
analyzed de-identified patient records and operations data utilizing
unique (baseline, not follow-up) visits of women accessing
screening. We focused on outcomes and trends of two key
program indicators: proportion of women who were HIV-
seropositive and proportion of women who were VIA-positive.
We compared clinical and demographic characteristics by HIV
serostatus utilizing Chi-square statistic for categorical variables
and the non-parametric Wilcoxon rank sum test for continuous or
ordinal variables [22]. We used logistic regression to identify
factors independently associated with VIA positivity, adjusting for
key clinical and demographic predictors (Age, education, marital
status, occupation, family income, number of lifetime sexual
partners, age of sexual debut, number of pregnancies, condom use
with regular partner, and HIV serostatus) that were selected apriori.
Missing values of predictors were multiply imputed to prevent
case-wise deletion [23]. To estimate programmatic trends, we
modeled the odds of key program indicators (HIV serostatus and
VIA positivity) with date of screening using restricted cubic splines,
and presented them as probabilities for ease of interpretation. The
analysis of VIA positivity is pooled across all years and assumes
that the associations of the correlates of VIA positivity remain
stable over time. R-software 2.11.1 (www.r-project.org ) was used
for statistical analyses.
This outcomes evaluation study of anonymized patient records
of a public sector implementation program was deemed exempt
from human subjects review or the need for informed consent by
the Research Ethics Committee of the University of Zambia.
Results
Screening Program Participant Characteristics by HIV
Serostatus
CCPPZ provided screening services for a total of 56427 women
in the period between January 2006 and April 2011 (date of data-
freeze for current analysis). A total of 17 clinics were operated by
17 nurses and an outpatient surgery care center housing a
Gynecologic Cancer Prevention Clinic. A total of 15081 (26.7%)
women were HIV-seropositive, 21322 (37.8%) were HIV-
seronegative, and 20024 (35.5%) reported not knowing their
HIV serostatus at the time of enrollment (Table 1, Figure 1).
The median age of screened women was 32 years (interquartile
range, IQR: 26–39). Over two-fifths (42.8%) of women with
recorded educational status reported receiving less than a high
school education. About a third (37.1%) of the screened
population was married and living with spouses while the rest
reported as being unmarried, widowed, or separated. Just over a
fifth of the screened women (21.1%) reported being employed in
the formal sector while over a third (35.7%) were housewives. A
majority (53.3%) lived on a family income of less than 500,000
Zambian Kwacha per month (approximately equivalent to
US$100). The median number of pregnancies reported was 3
(IQR: 2–5), the median number of lifetime sexual partners was 2
(IQR: 1–4) and just over a third (35.7%) reported ever use of a
condom with a regular partner (Table 1).
HIV-seropositive women were more likely to be older than
HIV-seronegative women (median age: 34 versus 29 years,
p,0.001). Higher proportion of HIV-seropositive women were
likely to be married (44.5% versus 33.9%, p,0.001), have less
education (46.3% versus 39.3%, p,0.001), and have family
incomes lower than 500,000 Zambian Kwacha per month (57.6%
versus 52.7%, p,0.001) than HIV-seronegative women (Table 1).
On average, HIV-seropositive women had a greater median
number of lifetime sexual partners [3 versus 2 partners, p,0.001],
while they reported higher rates of condom use with regular
partners (49.9% versus 33.2%, p,0.001) than HIV-seronegative
women (Table 1).
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Trends in Program Utilization by HIV-serologic Status
The relative proportion of women who were HIV-seropositive
as a share of the total women who utilized the screening services
declined over five years from 54% in 2006 to 23% in 2010.
Consequently, the proportion of HIV-seronegative women
increased in the same duration from 22% to 30%, while that of
women with unknown HIV serostatus went up from 24% in 2006
to 39% in 2010. All these trends were statistically significant
(p,0.001). The crude probability of the HIV serostatus of women
utilizing the screening services is graphically depicted in Figure 2.
Trends in Cervical Cancer Screening Results
Cumulatively between January 2006 and April 2011, out of the
total of 50,355 visual screening results available for analysis,
13,978 (27.7%) women were detected as VIA positive while
35,409 (70.3%) were VIA negative. Only a small minority (968,
1.9%) were classified as VIA-uncertain/indeterminate on initial
screening. The VIA positivity rates declined over time from 47%
in 2006 to 17% in 2010, and rates of VIA negativity increased
from 52% in 2006 to 82% in 2010. This decline in VIA positivity,
while directly coinciding with the increase in program scale-up
activities, was consistent regardless of changes in utilization
patterns by HIV serostatus, i.e., the crude probability of being
detected as VIA positive (Figure 3, Y-axis) declined statistically
significantly among women who were HIV-seropositive, HIV-
seronegative, as well as those whose HIV serostatus was unknown
(all p,0.001).
Factors Associated with Cervical Cancer Screening Test
Positivity
Overall, HIV-seropositive women had higher rates of VIA
positivity (40.9%) than HIV-seronegative women (20.3%), while a
quarter (25.2%) of women with unknown HIV serostatus were
VIA positive. After covariate-adjustment in a multivariable logistic
regression model, HIV-seropositive women had 2.62 times higher
odds of being detected as VIA positive [adjusted odds ratio (AOR)
2.62 (95% CI: 2.49, 2.76, p,0.001)] than HIV-seronegative
women (Table 2). Factors independently associated with VIA
positivity included younger age, education beyond high school,
having income under 500,000 Zambian Kwacha per month,
reporting two or more lifetime sexual partners, reporting lower age
of sexual debut and reporting ever using condoms with regular
partner (Table 2).
Discussion
VIA-based screening is increasingly being adopted for cervical
cancer prevention interventions in the developing world. CCPPZ
is the first and largest PEPFAR-supported VIA-cryotherapy based
‘screen-and-treat’ cervical cancer prevention initiative linked to
HIV/AIDS care and support programs in the developing world
Figure 1. Cumulative enrollment of women in the Cervical Cancer Prevention Program in Zambia (CCPPZ) between January 2006–
April 2011 by HIV serostatus.
doi:10.1371/journal.pone.0074607.g001
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Table 1. Sociodemographic characteristics of the women utilizing services of the Cervical Cancer Prevention Program in Zambia








(n =15081) (n =21322) (n =20024) (n=56427)
Age Median (IQR) 34 (29–40) 29 (24–37) 32 (26–40) 2 (26–39) ,0.001
Missing data, n (%) 197 (1.3%) 234 (1.1%) 302 (1.5%) 733 (1.3%)
Education, n (%) Less than high school 4703 (46.3%) 6615 (39.3%) 6752 (44.3%) 18070 (42.8%) ,0.001
High school completed 5464 (53.7%) 10225 (60.7%) 8480 (55.7%) 24169 (57.2%)
Missing 4914 (32.6%) 4482 (21.0%) 4792 (23.9%) 14188 (25.1%)
Marital status, n (%) Not Married 2882 (55.5%) 5847 (66.1%) 6306 (63.9%) 15035 (62.9%) ,0.001
Married 2312 (44.5%) 3001 (33.9%) 3562 (36.1%) 8875 (37.1%)
Occupation, n (%) House wife 2805 (30.7%) 5917 (39.3%) 4838 (35.1%) 13560 (35.7%) ,0.001
Formal sector 1982 (21.7%) 3301 (21.9%) 2723 (19.7%) 8006 (21.1%)
Informal sector 3226 (35.3%) 3659 (24.3%) 4387 (31.8%) 11272 (29.7%)
Other 1129 (12.3%) 2186 (14.5%) 1841 (13.4%) 5156 (13.6%)
Missing 5939 (39.4%) 6259 (29.4%) 6235 (31.1%) 18433 (32.7%)
Family income per month, n (%) Zambian kwacha #500,000 5666 (57.6%) 8501 (52.7%) 7565 (51.3%) 21732 (53.3%) ,0.001
Zambian kwacha .500,000 4178 (42.4%) 7644 (47.3%) 7193 (48.7%) 19015 (46.7%)
Missing 5237 (34.7%) 5177 (24.3%) 5266 (26.3%) 15680 (27.8%)
Number of lifetime sexual partners Median (IQR) 3 (2–5) 2 (1–3) 2 (1–3) 2 (1–4) ,0.001
Missing data, n (%) 263 (1.7%) 396 (1.9%) 902 (4.5%) 1561 (2.8%)
Number of pregnancies Median (IQR) 3 (2–5) 3 (2–5) 3 (2–5) 3 (2–5) n.s.
Missing data, n (%) 826 (5.5%) 2120 (9.9%) 2705 (13.5%) 5651 (10.0%)
Condom use with regular partner, n (%) Never 6855 (50.1%) 13104 (66.8%) 12383 (72.9%) 32342 (64.3%) ,0.001
Ever 6830 (49.9%) 6523 (33.2%) 4608 (27.1%) 17961 (35.7%)
Missing data 1396 (9.3%) 1695 (7.9%) 3033 (15.1%) 6124 (10.9%)
Footnotes: Abbreviation: IQR: interquartile range, HIV: human immunodeficiency virus, n.s.: not significant.
*p-value of comparison of characteristics between HIV-seropositive and HIV-seronegative women.
doi:10.1371/journal.pone.0074607.t001
Figure 2. Probability of individual HIV serostatus among
women utilizing services of the Cervical Cancer Prevention
Program in Zambia (CCPPZ).
doi:10.1371/journal.pone.0074607.g002
Figure 3. Probability of being detected as VIA positive
stratified by HIV-serostatus among women utilizing services
of the Cervical Cancer Prevention Program in Zambia (CCPPZ).
doi:10.1371/journal.pone.0074607.g003
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[10,19–21,24]. Developed initially as a program targeting HIV-
infected women (who had very high cervical disease burden
[25,26]); CCPPZ now screens a vast majority of women in the
implementation catchment areas who are not HIV-seropositive. In
this paper, we have provided the world’s first real-world
implementation-based evidence that even while focused on the
highest-risk HIV-infected women, utilization of ‘screen-and-treat’
programs by the broader general population occurs with sustained
efforts.
HIV/AIDS care and treatment programs provide very highly
suitable platforms for launching ‘screen-and-treat’ cervical cancer
prevention services, a very critical and life-saving intervention for
all eligible women, regardless of their HIV serostatus. As we have
demonstrated through this study, the increasing utilization of
program services by women other than who are HIV-seropositive
has coincided with program expansion in response to increased
demand, and greater acceptance and uptake of screening services
in the general population. Sustainability of the screening program
has been achieved through community involvement and contin-
ued training of non-physician community mobilizers and care
givers [27]. Scale-up of cervical cancer prevention interventions in
this high-HIV prevalence setting is being accompanied by efforts
for dispelling misconceptions that only ‘‘people with AIDS’’ could
suffer from cancer of the cervix, attempts for de-stigmatization of
cervical cancer in general, and improving the awareness and
importance of screening in particular [28]. Nevertheless, given
their increased risk for cervical cancer, it is important to continue
targeted screening efforts for HIV-seropositive women, particu-
larly linked to their cART clinic visits. The increased utilization of
screening services by women who have never tested for HIV, and
those who have previously (.6 months ago) tested seronegative,
also gave an opportunity to offer simultaneous counseling and
serological testing for HIV in the cervical cancer clinics for such
women. This activity has allowed linkages to care of women who
newly test HIV-seropositive, thereby achieving even greater
programmatic efficiencies (CCPPZ, unpublished data).
The successful scale up of cervical cancer screening activities
was aided by expansion from the initial 2 clinics in 2006 to 17
clinics by 2011 and from 5 nurses in 2006 to 17 nurses in 2011.
CCPPZ program nurses form the backbone of the ‘screen-and-
Table 2. Multivariable logistic regression model to identify factors associated with VIA screening test positivity among women
utilizing services of the Cervical Cancer Prevention Program in Zambia (CCPPZ) between January 2006–April 2011.
Risk of VIA positivity
Adjusted Odds ratio (95% CI) p-value
Age #25 years 1 (Referent) ,0.001
30 years 1.00 (0.97, 1.03)
35 years 0.87 (0.82, 0.91)
$40 years 0.74 (0.69, 0.79)
Education Less than high school 1 (Referent) ,0.001
High school completed 0.89 (0.85, 0.94)
Marital Status Not married 1 (Referent) 0.155
Married 0.95 (0.88, 1.02)
Occupation House wife 1 (Referent) 0.930
Formal sector 1.00 (0.91, 1.09)
Informal sector 1.01 (0.93, 1.08)
Other 0.98 (0.90, 1.07)
Family income per month Zambian kwacha #500,000 1 (Referent) 0.003
Zambian kwacha .500,000 0.92 (0.87, 0.97)
Number of lifetime sexual partners 1 partner 1 (Referent) ,0.001
2 partners 1.10 (1.04, 1.16)
3 partners 1.16 (1.10, 1.23)
4 partners 1.20 (1.13, 1.27)
Age of sexual debut (per year increase) 0.98 (0.98, 0.99) ,0.001
Number of pregnancies 1 1 (Referent) ,0.001
3 1.16 (1.09, 1.23)
5+ 1.02 (0.95, 1.10)
Condom use with regular partner Never 1 (Referent) ,0.001
Ever 1.17 (1.11, 1.22)
HIV serostatus HIV-seronegative 1 (Referent) ,0.001
HIV-seropositive 2.62 (2.49, 2.76)
HIV serostatus unknown 1.41 (1.34, 1.48)
Footnotes: Abbreviations: VIA: visual inspection with acetic acid, HIV: human immunodeficiency virus.
Following a post hoc adjustment for date of screening to account for potential confounding effect of calendar time, the covariate associations are unchanged in
direction of effect size as well as tests of significance.
doi:10.1371/journal.pone.0074607.t002
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treat’-based program operations. They function as the primary
care givers independently performing screening and same-visit
cryotherapy procedures, and refer patients needing histologic
evaluation to tertiary care facilities. The training of nurses has
been a vital component, largely achieved through a train-the-
trainer model, where nurses serve as educators for their peers. This
model has also proven successful in training nurses from 12 other
African countries who have received on-site clinically-mentored
training within CCPPZ-supported government clinics as part of a
global cervical cancer training program.
One of the most important factors in the improvement of VIA
performance is the use of digital camera enhancement of the
cervix (‘digital cervicography’), a low-cost adaptation for the
Zambian setting. This is modeled after colposcopy, yet does not
require a costly colposcope or prolonged training [19,29–31]. It
also has substantial collateral benefits, including the ability to
project the cervical image on the camera monitor or a bedside
television/computer screen for patients to visualize simultaneously
(thereby achieving patient education), electronic transmission of
the image by email or cellphone to a consulting gynecologist for
telemedicine support for decision making (if needed), and the
ability to routinely undertake quality assurance on the images [19].
These attributes have allowed for overall reductions in the
misclassifications of VIA, as reflected by the decreasing rates of
VIA positivity over the 2006–2011 calendar years period. As a
rater-dependent screening method, VIA inherently suffers from
the same challenges as other visual interpretation methods
including colposcopy and cytology [16–18]. The greater the
experience and number of procedures performed correctly by the
provider, the less the chances of errors. Indeed, one of the most
common criticisms of VIA is the tendency to ‘overcall’ an
acetowhite appearing cervix as ‘VIA positive’. However, as we
have shown in this study, with the increase in the experience of
nurses undertaking screening (as reflected by the total number of
women utilizing the screening services), the rate of VIA positivity
has fallen substantially, regardless of the HIV serostatus. Since the
eventual successes in reduction of cervical cancer burden will be
dependent on how well are screening services implemented in a
particular setting, this unique demonstration through program
operations data underscores the importance of a sustained focus
on evaluation, training and quality improvement in screening
implementation.
In the wake of projections of a startling rise in new cancer cases
and deaths in Africa over the next 20 years [32,33], our experience
in initiating and expanding cervical cancer ‘screen-and-treat’
services in Zambia may provide useful insights for African
governments and their international partners as they consider
implementing cancer prevention initiatives, especially in high HIV
prevalence settings, to mitigate this impending tragedy.
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